Introduction
============

The role of sugars in the development of cardiometabolic disease is actively debated.[@ref1] [@ref2] In particular, fructose has recently emerged as a serious public health concern, as ecological parallels have been drawn between the introduction of high fructose corn syrup (HFCS) as a popular sweetener during the 1970s and global rises in obesity and diabetes prevalence.[@ref3] [@ref4]

Despite early considerations for the use of fructose as an alternative sweetener in people with diabetes, owing to its observed potential to lower postprandial glycaemic excursions when compared with isocaloric amounts of starch,[@ref5] increasing evidence has suggested that fructose could be particularly detrimental to metabolic health, and even more so than other sugars.[@ref6] This view has received support from ecological evidence[@ref4] as well as animal studies[@ref7] [@ref8] [@ref9] and select human intervention studies.[@ref10] [@ref11] [@ref12] However, higher levels of evidence from systematic reviews and meta-analyses of controlled human intervention studies have failed to show adverse glycaemic effects unique to fructose, and have even shown a beneficial effect on glycated blood proteins of fructose in isocaloric substitution for other carbohydrates in the diet in people with diabetes.[@ref13]

Whether a causal link exists between fructose and the development of diabetes and related cardiometabolic comorbidities continues to be contested. But much less appreciated in this debate are the consumption patterns and levels at which fructose is normally consumed in the diet. Fructose is rarely consumed in isolation under real world conditions.[@ref14] It is present in various food sources containing comparable amounts of glucose, and the proportion of fructose co-ingested with glucose has been suggested to influence fructose metabolism.[@ref15] In its most commonly consumed form, sucrose (table sugar), fructose is part of a disaccharide with glucose in a 50:50 ratio. HFCS is also a glucose-fructose mix, with varying fructose content (42-55% molecular weight) in a free, unbound monosaccharide form. Similarly, less refined sources of fructose-containing sugars---including honey, agave, and maple syrup---are composed of varying proportions of fructose and glucose, while natural sources of fructose present in various fruit and vegetables also co-exist with glucose. These fructose-containing sugars are found in the diet in a variety of food sources, ranging from "nutrient poor" sources of added sugars (such as sugars-sweetened beverages (SSBs)), to "nutrient dense" sources of bound sugars (such as fruit). Evidence from prospective cohorts on diabetes risk have shown different associations depending on the food source of the sugars (that is, positive associations with SSBs[@ref16] [@ref17] and inverse association with fruit[@ref18] [@ref19]).

As dietary guidelines shift from nutrient based recommendations to more food and dietary pattern based recommendations,[@ref20] [@ref21] it is important to understand the role of the food matrix in modifying the effect of fructose-containing sugars. Current recommendations from the World Health Organization, United States, and United Kingdom have focused on the reduction of added or free sugars (added sugars plus sugars contained in fruit juices) to less than 5-10% energy,[@ref20] [@ref22] [@ref23] especially free fructose-containing sugars from SSBs.[@ref20] Whether the evidence for added or free sugars and SSBs can be generalised to all food sources of fructose-containing sugars in relation to their effects on surrogate markers of type 2 diabetes has not yet been determined. We conducted a systematic review and meta-analysis of controlled intervention studies to determine the effect of food sources of fructose-containing sugars at different levels of energy control on glycaemic control in people with and without diabetes.

Methods
=======

This systematic review and meta-analysis was conducted according to the Cochrane Handbook for Systematic Reviews and Interventions,[@ref24] with all results reported according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines.[@ref25] The study protocol was registered at Clinicaltrials.gov (NCT02716870).

Data sources
------------

Medline, Embase, and the Cochrane Central Register of Controlled Studies were searched up to 25 April 2018. We used the following search terms: fructose OR dietary sucrose, OR HFCS OR sugar OR sugar\* sweetened beverage\* OR honey AND glyc?em\* OR insulin OR HbA1c OR fructosamine OR blood glucose OR gly\* albumin (supplementary table 1). Validated filters from the McMaster University Health Information Research Unit were applied to limit the database search to controlled studies only,[@ref26] and electronic searches were supplemented with manual searches of references from included studies.

Study selection
---------------

We included reports of controlled intervention studies lasting at least seven days and comparing the effect of diets of fructose-containing sugars (fructose, sucrose, HFCS, honey, syrups) from various food sources with control diets free of or lower in these sugars on outcome measures of glycaemic control (fasting glucose, fasting insulin, and glycated haemoglobin (HbA1c)) in people with and without diabetes. We excluded reports of studies of meal replacements and studies of interventions of rare sugars that contained fructose (eg, isomaltulose or melzitose) or were low calorie epimers of fructose (eg, allulose, tagatose, sorbose), and reports of studies that used these sugars as the comparator. Four study designs based on the control of energy were prespecified:

-   Substitution studies, in which food sources of fructose-containing sugars were compared with food sources of other non-fructose-containing macronutrients under energy matched conditions (isocaloric comparison).

-   Addition studies, in which excess energy from food sources of fructose-containing sugars was added to background diets compared with the same background diets alone without the excess energy from fructose-containing sugars, with or without the use of low calorie sweeteners to match sweetness (hypercaloric comparison).

-   Subtraction studies, in which energy from food sources of fructose-containing sugars was subtracted from background diets through displacement by water or low calorie sweeteners, or by elimination of the food sources of fructose-containing sugars altogether compared with the original background diets (hypocaloric comparison).

-   Ad libitum studies, in which food sources of fructose-containing sugars were compared with food sources of other non-fructose-containing macronutrients without any strict control of either the study foods or the background diets, to allow for free replacement of the energy from fructose-containing sugars with the energy from other macronutrients (free-feeding comparison).

We included reports containing both randomised and non-randomised controlled intervention studies. An intervention study was considered non-randomised if the authors explicitly stated that a method of randomisation was not used or randomisation was not reported in the allocation of participants to the intervention or control treatments in parallel designs or the sequence of the treatments in crossover designs. In reports containing more than one study comparison, we included all available study comparisons.

Data extraction
---------------

Data from included reports were individually extracted at least twice by four separate reviewers. Relevant information included number of participants, setting, underlying disease status of participants, study design, level of feeding control, randomisation, comparator, fructose-containing sugars type, food sources of fructose-containing sugars, macronutrient profile of the diets, follow-up duration, energy balance, and funding sources. The three outcome variables were HbA1c, fasting blood glucose, and fasting blood insulin. HbA1c was reported instead of total glycated blood proteins as originally indicated in our protocol (identification number NCT02716870), because mean differences for these values were considered more clinically relevant and did not require the use of standardised mean differences needed to the different glycated blood proteins. Authors were contacted for missing outcome data when it was indicated that an outcome was measured but not reported. In the absence of numerical values for outcome measurements and inability to obtain the original data from authors, values were extracted from figures using Plot Digitizer where available.[@ref1] All discrepancies between reviewers were resolved through consensus or, where necessary, arbitration by the senior author.

Study quality
-------------

Included studies were assessed for risk of bias by at least two of the reviewers using the Cochrane Collaboration risk of bias tool[@ref27]. Final assessments were based on consensus between reviewers.

Data synthesis and analysis
---------------------------

We used Review Manager (RevMan) version 5.2 for primary analyses and Stata (version 12) for subgroup, dose response, and publication bias analyses. We performed separate analyses for the four prespecified study designs based on the control of energy (substitution, addition, subtraction, and ad libitum studies), and stratified analyses by food sources of sugars for each of three outcome variables (HbA1c, fasting blood glucose, and fasting blood insulin). The principal effect measure was the mean pairwise difference in change from baseline (or, when not available, the post-treatment value) between the food sources of the fructose-containing sugars arm and the comparator arm (reporting results as mean differences with 95% confidence intervals). We extracted the estimates of the mean differences and corresponding 95% confidence intervals for each outcome. Change-from-baseline differences were preferred over end differences, and paired analyses were applied to all crossover trials with the use of a within-individual correlation coefficient between treatments of 0.5 as described by Elbourne and colleagues.[@ref28]

When at least two studies provided data, we performed a DerSimonian and Laird random effects meta-analysis. When fewer than five studies were available for analysis, we also considered fixed effect estimates. Heterogeneity was assessed by the Cochran Q test (significant at P\<0.10) and quantified by the I^2^ statistic (range 0-100%).[@ref29] The interaction between fructose-containing sugars and food source was assessed by use of the χ^2^ statistic. Other sources of heterogeneity were explored by sensitivity and subgroup analyses. We carried out sensitivity analyses by systematically removing each study from the meta-analyses and recalculating the summary association. A study whose removal explained the heterogeneity, changed the significance of the effect, or altered the effect size by 10% or more was considered an influential study. If 10 or more studies per outcome were available,[@ref30] [@ref31] we conducted a priori subgroup analyses using meta-regression. Categorical subgroup analyses were done for energy balance (positive, neutral, negative), comparator (starch, glucose, fat, lactose, maltrodextrin, diet alone, water, non-nutritive sweeteners, protein, mixed sources), fructose-containing sugars type (fruit, sucrose, fructose, HFCS, honey), fructose-containing sugars dose (≤10%, \>10% energy[@ref22] [@ref32]), baseline HbA1c values (≤7%, \>7%), fasting glucose (≤5.5, \>5.5 mmol/L based on median values) and insulin (≤96.6, \>96.6 pmol/L based on median values), age (≤18, \>18 years), study design (crossover, parallel), follow-up duration (\<8, ≥8 weeks), randomisation (yes, no), level of feeding control (supplemented, dietary advice, and metabolically controlled), underlying disease status (diabetes, overweight/obese, metabolic syndrome criteria, otherwise healthy), and individual domains of risk of bias (sequence generation, allocation concealment, blinding of participants/personnel and outcome assessors, incomplete outcome data, selective outcome reporting).

We performed continuous dose-response analyses using meta-regression to assess linear dose-response gradients and non-linear meta-regression (MKSPLINE procedure) with knots at the public health thresholds of 5%,[@ref22] [@ref23] 10%,[@ref22] [@ref33] and 25% [@ref34] energy, to assess non-linear dose-threshold effects. If 10 or more studies per outcome were available,[@ref35] we assessed publication bias by inspection of funnel plots and formal testing with the Egger and Begg tests. If we saw evidence of publication bias, we used the Duval and Tweedie trim and fill method to adjust for funnel plot asymmetry by imputing missing study data.[@ref36]

Grading of the evidence
-----------------------

We used the GRADE approach (grading of recommendations assessment, development, and evaluation) to assess the certainty in our estimates and produce evidence profiles[@ref37] using GRADEpro GDT (GRADEpro Guideline Development Tool software, McMaster University, Canada, 2015). Evidence was graded as high, moderate, low, or very low quality. Included controlled intervention studies were graded as high quality evidence by default and downgraded on the basis of prespecified criteria. Criteria to downgrade evidence included risk of bias (assessed by the Cochrane risk of bias tool), inconsistency (substantial unexplained heterogeneity, I^2^\>50%, P\<0.10), indirectness (presence of factors that limited the generalisability of the results), imprecision (if the 95% confidence interval for pooled effect estimates crossed a minimally important difference for benefit or harm for HbA1c (0.3% difference), fasting blood glucose (0.5 mmol/L difference), and fasting blood insulin (10 pmol/L difference)), and publication bias (significant evidence of publication bias).

Patient and public involvement
------------------------------

Patient and public involvement was not included in this study. We were unable to involve any patients or members of the public in the design or conduct of the study, development of patient relevant outcomes, interpretation of the results, or writing or editing of the manuscript.

Results
=======

Search results
--------------

[Figure 1](#f1){ref-type="fig"} shows the systematic search and selection of literature. Of 4442 reports identified from database and manual searches, 4157 were excluded on the basis of the title and abstract. Of 285 reports reviewed in full, an additional 164 reports were excluded for failure to meet the eligibility criteria. The final analysis included 118 reportsof controlled intervention studies,[@ref5] [@ref11] [@ref12] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] [@ref71] [@ref72] [@ref73] [@ref74] [@ref75] [@ref76] [@ref77] [@ref78] [@ref79] [@ref80] [@ref81] [@ref82] [@ref83] [@ref84] [@ref85] [@ref86] [@ref87] [@ref88] [@ref89] [@ref90] [@ref91] [@ref92] [@ref93] [@ref94] [@ref95] [@ref96] [@ref97] [@ref98] [@ref99] [@ref100] [@ref101] [@ref102] [@ref103] [@ref104] [@ref105] [@ref106] [@ref107] [@ref108] [@ref109] [@ref110] [@ref111] [@ref112] [@ref113] [@ref114] [@ref115] [@ref116] [@ref117] [@ref118] [@ref119] [@ref120] [@ref121] [@ref122] [@ref123] [@ref124] [@ref125] [@ref126] [@ref127] [@ref128] [@ref129] [@ref130] [@ref131] [@ref132] [@ref133] [@ref134] [@ref135] [@ref136] [@ref137] [@ref138] [@ref139] [@ref140] [@ref141] [@ref142] [@ref143] [@ref144] [@ref145] [@ref146] [@ref147] [@ref148] [@ref149] [@ref150] [@ref151] [@ref152] including a total of 155 study comparisons in 5086 participants.

![Flow of literature for the effect of food sources of fructose-containing sugars on glycaemic control](chov038661.f1){#f1}

Study characteristics
---------------------

[Table 1](#tbl1){ref-type="table"} provides a summary of the mean study characteristics by the four prespecified study designs (substitution, addition, subtraction, and ad libitum studies), with a breakdown of individual study characteristics in supplementary table 2. Study sizes were relatively small, ranging from a median of 15 participants (range 6-318) in subtraction studies to 39 participants (8-236) in ad libitum studies. Most studies were performed in an outpatient setting, with almost half of all substitution (43/108), addition (12/35), and subtraction (1/5) studies conducted in the US, and all ad libitum studies conducted in European countries. Participants tended to be middle aged, with roughly equal ratios of men to women in substitution, addition, and ad libitum studies, but proportionately more women than men in subtraction studies. Most studies included individuals with diabetes (34%, 37/108) or otherwise healthy participants (26%, 28/108) in substitution studies; otherwise healthy (34%, 12/35) or overweight or obese participants (29%, 10/35) in addition studies; overweight or obese participants (80%, 4/5) in subtractions studies; and otherwise healthy participants (43%, 3/7) in ad libitum studies.

###### 

Summary of study characteristics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study characteristics                                                                     Substitution studies                                                                                                                                     Addition studies                                                                                                                                                 Subtraction studies                         Ad libitum studies
  ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------
  Study comparisons (No)                                                                    108                                                                                                                                                      35                                                                                                                                                               5                                           7

  Study size (median No (range) of participants)                                            15 (5-595)                                                                                                                                               20 (6-63)                                                                                                                                                        15 (6-318)                                  39 (8-236)

  Men:women ratio (%)                                                                       42:58                                                                                                                                                    46:54                                                                                                                                                            12:88                                       41:59

  Age (years; median (interquartile range))                                                 39.8 (24.7-53.8)                                                                                                                                         36.2 (27.4-49.4)                                                                                                                                                 33.5 (29.1-41.9)                            38 (34-39.8)

  Setting (%; inpatients, outpatients, inpatients/outpatients)                              10, 75, 15                                                                                                                                               3, 89, 9                                                                                                                                                         0, 100, 0                                   0, 100, 0

  Baseline fasting glucose (mmol/L; median (interquartile range))                           5.4 (4.9-8.5)                                                                                                                                            5.1 (4.9-5.4)                                                                                                                                                    5.1 (5.1-5.2)                               4.9 (4.9-5.4)

  Baseline fasting insulin (pmol/L; median (interquartile range))                           96.6 (57.9-128.5)                                                                                                                                        50.4 (40.6-81.4)                                                                                                                                                 109.8 (97.8-121.7)                          32.8 (32.1-45.9)

  Baseline HbA1c (%; median (interquartile range))                                          7.5 (6.8-8.5)                                                                                                                                            6.8 (5.5-7.1)                                                                                                                                                    Baseline data only reported for one study   Baseline data only reported for one study

  Study design (%; crossover:parallel)                                                      61:39                                                                                                                                                    49: 51                                                                                                                                                           20: 80                                      57: 43

  Feeding control (%; met, supp, DA)                                                        44, 41, 16                                                                                                                                               13, 80, 7                                                                                                                                                        0, 70, 30                                   50, 37.5, 12.5

  Randomisation (%; yes:no)                                                                 72:28                                                                                                                                                    66:34                                                                                                                                                            80:20                                       100:0

  Fructose-containing sugar dose (% of total energy intake; median (interquartile range))   15.0 (9.3-22.1)                                                                                                                                          12.2 (7.7-25.0)                                                                                                                                                  15.0 (11.3-15.0)                            23.0 (13.0-26.0)

  Follow-up duration (median No (range) of weeks)                                           4.5 (1-52)                                                                                                                                               6 (1-24)                                                                                                                                                         12 (1-36)                                   8 (2-76)

  Funding sources (%; ag, ind, ag-ind, not reported)                                        32, 18, 28, 22                                                                                                                                           49, 9, 34, 9                                                                                                                                                     60, 40, 0, 0                                0, 17, 50, 33

  Fructose-containing sugar type (No of studies)                                            Fructose=47, fruit=17, HFCS=3, sucrose=48, honey=2                                                                                                       Fructose=8, fruit=13, HFCS=1, honey=4, sucrose=9                                                                                                                 Sucrose=5, HFCS=4                           Fructose=1, sucrose=7

  Comparator (No of studies)                                                                Fat=7, glucose=23, lactose=5, maltodextrin=1, mixed comparator=14, protein=1, starch=53, diet alone=3, water=1                                           Diet alone=27, sweetener=4; water=5                                                                                                                              Water=2, sweetener=3, no sucrose=1          Fat=2, mixed comparator=2, starch=4, sweetener=3

  Food sources of\                                                                          Fruit=12; dried fruit=4; fruit juice=1; SSBs=21; sweetened low fat milk=2; baked goods, sweets, and desserts=11; added sweeteners=12; mixed sources=45   Fruit=9; dried fruit=1; fruit juice=3; fruit drink=3; SSBs=12; sweetened chocolate=1; baked goods, sweets, and desserts=1; added sweeteners=4; mixed sources=1   Mixed sources=1, SSBs=4                     Baked goods, sweets, and desserts=1; mixed sources=6
  fructose-containing sugars (No of studies)                                                                                                                                                                                                                                                                                                                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ag=agency; ag-ind=agency-industry; DA=dietary advice; E=energy; HbA1c=glycated haemoglobin; HFCS=high fructose corn syrup; ind=industry; met=metabolically controlled; SSBs=sugars-sweetened beverages; supp=supplemented.

Most studies were randomised (72% (78/108) of substitution studies, 66% (23/35) of addition studies, 80% (4/5) of subtraction studies, and 100% (7/7) of ad libitum studies). Follow-up duration was relatively short, ranging from a median of 4.5 weeks (range 1-52 weeks) in substitution studies to 12 weeks (1-36) in subtraction studies. Doses of fructose-containing sugars ranged from a median of 12.2% (range 7.7-25.0%) of total energy intake in addition studies to 23% (13.0-26.0%) in ad libitum studies, and were mostly in the form of mixed food sources in substitution (45/108) and ad libitum (6/7) studies while most addition studies (12/35) and subtraction studies (4/5) used SSBs. Most studies were funded by agency sources (government, not-for-profit health agency, or university sources), except for ad libitum trials, which were primarily funded by agency-industry funding.

Study quality
-------------

Supplementary figure 1 shows a summary of the risk of bias assessments by the Cochrane risk of bias tool. Owing to poor reporting standards, most studies were assessed as having unclear risk of bias across the five domains of bias. Few studies were assessed as having high risk of bias, with only 20.3% (24/118), 23.7% (28/118), 1.7% (2/118), 8.5% (10/118) of studies assessed as high risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, and incomplete outcome data, respectively. Overall, no serious risk of bias was detected.

Outcomes
--------

### HbA1c

[Figure 2](#f2){ref-type="fig"} and supplementary figures 2-5 show the effect of different food sources of fructose-containing sugars on HbA1c levels. Total fructose-containing sugars independent of food sources showed a significant beneficial effect on HbA1c in substitution studies (30 study comparisons, mean difference −0.22% (95% confidence interval −0.35% to −0.08%), −25.9 mmol/mol (95% confidence interval −27.3 to −24.4), P\<0.01, substantial heterogeneity (I^2^=82%, P\<0.001)). We saw no significant effect in addition studies (six study comparisons, substantial heterogeneity (I^2^=83%, P\<0.001)), subtraction studies (one study comparison), or ad libitum studies (one study comparison). Although formal tests of interaction by food source were not significant in the substitution or addition studies, an interaction appeared to be present in the substitution studies, with fruit being the major driver of the effect. Fruit accounted for 30% of the weighted benefit as the only food source, showing a significant decrease in HbA1c (six study comparisons, mean difference −0.19% (95% confidence interval −0.35 to −0.03), −25.6 mmol/mol (95% confidence interval −27.3 to −23.8), P=0.02, substantial heterogeneity (I^2^=78%, P\<0.001)). An interaction by food source could not be assessed at the other levels of energy control, because only one food source category was assessed in the subtraction studies (SSBs) and ad libitum studies (baked goods, sweets, and desserts).

![Summary plot for the effect of food sources of fructose-containing sugars on glycated haemoglobin (HbA1c). Data are weighted mean differences (95% confidence intervals) for summary effects of individual food sources and total food sources on HbA1c. Analyses conducted by generic, inverse variance random effects models (at least five trials available) or fixed effects models (fewer than five trials available). Interstudy heterogeneity was tested by the Cochran's Q statistic (χ^2^) at a significance level of P\<0.10](chov038661.f2){#f2}

Sensitivity analyses for HbA1c are presented in supplementary table 3. The removal of each study did not explain the heterogeneity or change the significance of the effect. A priori subgroup analyses for HbA1c are presented in supplementary figures 6 and 7 and dose-response analyses for HbA1c are presented in supplementary figures 8 and 9. A priori subgroup analyses did not show any effect modification in substitution studies. We saw evidence of a dose threshold seen at 10% energy by MKSPLINE procedure with the largest decreases seen only at doses up to 10% energy (P=0.04). No subgroup or dose-response analyses were conducted for addition, subtraction, or ad libitum studies, because fewer than 10 studies were available for analyses.

### Fasting blood glucose

[Figure 3](#f3){ref-type="fig"} and supplementary figures 10-13 show the effect of different food sources of fructose-containing sugars on fasting blood glucose. Total fructose-containing sugars independent of food sources had no effect on fasting blood glucose in substitution studies (99 study comparisons, substantial heterogeneity (I^2^=65%, P\<0.001)), addition studies (28, substantial heterogeneity (I^2^=71%, P\<0.001)), subtraction studies (four, substantial heterogeneity (I^2^=59%, P=0.06)), or ad libitum studies (six, no evidence of heterogeneity). We saw a significant interaction by food source in addition studies (P=0.01): SSBs (11 study comparisons, mean difference 0.12 mmol/L (95% confidence interval 0.03 to 0.22), substantial heterogeneity (I^2^=74%), P\<0.001) and fruit juice (two, 0.29 mmol/L (0.09 to 0.49), no evidence of heterogeneity) showed a significant harmful effect. However, fruit (six study comparisons), dried fruit (one study comparison), fruit drinks (three), sweetened chocolate (one), added sweeteners (three), and mixed sources (one) showed no significant effect on fasting blood glucose. No significant interaction by food source was seen in the substitution, subtraction, or ad libitum studies, although only one food source category was assessed in the subtraction studies (SSBs) and ad libitum studies (mixed sources).

![Summary plot for the effect of food sources of fructose-containing sugars on fasting blood glucose. Data are weighted mean differences (95% confidence intervals) for summary effects of individual food sources and total food sources on fasting blood glucose. Analyses conducted by generic, inverse variance random effects models (at least five trials available) or fixed effects models (fewer than five trials available). Interstudy heterogeneity was tested by the Cochran's Q statistic (χ^2^) at a significance level of P\<0.10](chov038661.f3){#f3}

Supplementary table 3 shows the sensitivity analyses for fasting blood glucose. Removal of any one of six addition studies[@ref38] [@ref46] [@ref72] [@ref105] [@ref114] [@ref123] changed the estimates from non-significant to significant, but did not change the magnitude or direction of the effect or the evidence of substantial heterogeneity. Removal of the 2015 subtraction study by Campos and colleagues (group 2)[@ref60] explained all of the heterogeneity, changing the direction but not the lack of significance of the effect on fasting blood glucose. Finally, removal of the 2012 subtraction study by Tate and colleagues[@ref148] explained most of the heterogeneity (I^2^=32%, P=0.23) but did not change the direction or lack of significance of the effect on fasting blood glucose.

A priori subgroup analyses for fasting blood glucose are presented in supplementary figures 14-17, and dose-response analyses for fasting blood glucose are presented in supplementary figures 8 and 9. We saw significant effect modification by dose of fructose-containing sugars (≤10% energy or \>10% energy), with a further threshold effect (25% energy) identified by the MKSPLINE procedure, comparator (starch, glucose, fat, mixed, lactose, dairy), baseline fasting blood glucose (≤5.5 mmol/L or \>5.5 mmol/L), feeding control (dietary advice, supplementation, or metabolically controlled), or underlying disease status (otherwise healthy, overweight/obese, diabetes, metabolic syndrome, or non-alcoholic fatty liver disease) in the substitution studies (P\<0.05). We also observed a significant subgroup effect by baseline fasting blood glucose (≤5.5 mmol/L or \>5.5 mmol/L) in addition studies (P=0.01). None of the subgroup or dose-response analyses explained the substantial heterogeneity in the substitution and addition studies. No subgroup or dose-response analyses were conducted for subtraction or ad libitum comparisons because fewer than 10 studies were available for analyses.

### Fasting blood insulin

[Figure 4](#f4){ref-type="fig"} and supplementary figures 18-21 show the effect of different food sources of fructose-containing sugars on fasting blood insulin. Total fructose-containing sugars independent of food sources had a harmful effect on fasting blood insulin in addition studies (23 study comparisons, mean difference 4.68 pmol/L (95% confidence interval 1.40 to 7.96), P\<0.01, substantial heterogeneity (I^2^=58%, P\<0.001)) and ad libitum studies (four, 7.24 pmol/L (0.47 to 14.00), P=0.04, no evidence of heterogeneity (I^2^=0%, P=0.46)). We saw no effect in substitution studies (70 studies, substantial heterogeneity (I^2^=61%, P\<0.001)) or subtraction (three, substantial heterogeneity (I^2^=79%, P\<0.01)).

![Summary plot for the effect of food sources of fructose-containing sugars on fasting blood insulin. Data are weighted mean differences (95% confidence intervals) for summary effects of individual food sources and total food sources on fasting blood insulin. Analyses conducted by generic, inverse variance random effects models (at least five trials available) or fixed effects models (fewer than five trials available). Interstudy heterogeneity was tested by the Cochran Q statistic (χ^2^) at a significance level of P\<0.10](chov038661.f4){#f4}

We saw a significant interaction by food source in substitution studies (P\<0.001). Fruit juice (one study comparison, mean difference −13.89 pmol/L (95% confidence interval −27.50 to −0.28), P=0.05) showed a beneficial effect, and sweetened low fat milk (two, 18.95 pmol/L (9.09 to 28.80), P\<0.001, no evidence of heterogeneity) and mixed sources (25, 7.74 pmol/L (2.94 to 12.53), P\<0.01, no substantial heterogeneity) showed a harmful effect. Fruit (six study comparisons, no evidence of heterogeneity); dried fruit (one); SSBs (17); baked goods, sweets, and desserts (10, no evidence of heterogeneity); and added sweeteners (eight, substantial heterogeneity (I^2^=83, P\<0.001)) showed no significant effect on fasting blood insulin. No significant interaction by food source was seen in the addition, ad libitum, or subtraction studies, although SSBs accounted for more than 50% of the weighted harm in addition studies and mixed sources was the exclusive food source of fructose-containing sugars in the ad libitum studies.

Sensitivity analyses for fasting blood insulin are presented in supplementary table 3. Removal of the 2009 addition study by Hollis and colleagues[@ref83] explained some of the heterogeneity (I^2^=42%, P=0.02) without changing the significance, magnitude, or direction of the effect. Removal of either one of two substitution studies[@ref92] [@ref104] changed the evidence from non-significant to significant without changing the magnitude or direction of the effect or the evidence of substantial heterogeneity. Removal of the subtraction study by Campos and colleagues (group 2)[@ref60] explained nearly all of the heterogeneity (I^2^=1%, P=0.31), changing the significance and magnitude but not the direction of the effect. Removal of the 2000 ad libitum study by Raben and colleagues (C)[@ref124] eliminated the evidence for the significance but not the direction of the effect or evidence of no substantial heterogeneity.

A priori subgroup analyses for fasting blood insulin are presented in supplementary figures 22-25, and dose-response analyses for fasting blood insulin are presented in supplementary figures 8 and 9. We saw significant effect modification in substitution studies by level of feeding control (dietary advice, supplementation, or metabolically controlled) or by risk of bias for blinding of participants, personnel, and outcome assessors (low, high, or unclear) in the substitution studies (P\<0.05). None of the subgroup or dose-response analyses explained the substantial heterogeneity in the substitution studies. No subgroup or dose-response analyses were significant in the addition studies. No subgroup analyses were conducted for the subtraction or ad libitum studies, because fewer than 10 studies were available for analyses.

Publication bias
----------------

Supplementary figures 26 and 27 show the publication bias assessment for all analyses where at least 10 studies were available. We saw no evidence of publication bias for the effect of food sources of fructose containing sugars on HbA1c, fasting blood glucose, or fasting blood insulin. Although the Begg test was significant (P=0.04), visual inspection of funnel plots and the Egger test did not show evidence of publication bias for the effect of food sources of fructose containing sugars on fasting blood glucose in substitution studies. Adjustment for funnel plot asymmetry by the Duval and Tweedie method also did not alter the results.

GRADE assessment
----------------

[Table 2](#tbl2){ref-type="table"} shows a summary of the overall quality of evidence assessment for the effect of total fructose-containing sugars independent of food source on the outcome measures of glycaemic control. The certainty in the evidence was variable for HbA1c (low, low, low, and low quality), fasting blood glucose (low, low, moderate, and moderate), and fasting blood insulin (low, low, low, and moderate) across substitution, addition, subtraction, and ad libitum studies, respectively. Evidence for HbA1c was downgraded for inconsistency in substitution and addition studies; for indirectness in subtraction and ad libitum studies; and for imprecision in substitution, addition, subtraction, and ad libitum studies. Evidence for fasting blood glucose was downgraded for inconsistency in substitution and addition studies; and for imprecision in substitution, addition, subtraction, and ad libitum studies. Similarly, evidence for fasting blood insulin was downgraded for inconsistency in the substitution, addition, and subtraction studies; and for imprecision in substitution, addition, subtraction, and ad libitum studies.

###### 

GRADE quality of evidence assessment for the effect of fructose-containing sugars on outcome measures of glycaemic control, by study type

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type and No of studies      Study design                    Quality assessment        Quality                                                                        
  --------------------------- ------------------------------- ------------------------- ---------------------------- ------------------------- --------------- ------- ----------
  **HbA1c**                                                                                                                                                            

  Substitution (n=30)         Randomised and non-randomised   No serious risk of bias   Serious\*                    No serious indirectness   Serious\*       None    ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Addition (n=6)              Randomised and non-randomised   No serious risk of bias   Serious†                     No serious indirectness   Serious†        None    ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Subtraction (n=1)           Randomised and non-randomised   No serious risk of bias   No serious inconsistency‡    Serious§                  Serious§        None‡   ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Ad libitum (n=1)            Randomised and non-randomised   No serious risk of bias   No serious inconsistency‡    Serious¶                  Serious¶        None‡   ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  **Fasting blood glucose**                                                                                                                                            

  Substitution (n=99)         Randomised and non-randomised   No serious risk of bias   Serious\*\*                  No serious indirectness   Serious\*\*     None    ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Addition (n=28)             Randomised and non-randomised   No serious risk of bias   Serious††                    No serious indirectness   Serious††       None    ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Subtraction (n=4)           Randomised and non-randomised   No serious risk of bias   No serious inconsistency‡‡   No serious indirectness   Serious‡‡       None‡   ⊕⊕⊕Ο\
                                                                                                                                                                       Moderate

  Ad libitum (n=6)            Randomised and non-randomised   No serious risk of bias   No serious inconsistency     No serious indirectness   Serious§§       None‡   ⊕⊕⊕Ο\
                                                                                                                                                                       Moderate

  **Fasting blood insulin**                                                                                                                                            

  Substitution (n=70)         Randomised and non-randomised   no serious risk of bias   Serious¶¶                    No serious indirectness   Serious¶¶       None    ⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Addition (n=23)             Randomised and non-randomised   No serious risk of bias   Serious\*\*\*                No serious indirectness   Serious\*\*\*   None    ⊕⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Subtraction (n=3)           Randomised and non-randomised   No serious risk of bias   Serious†††                   No serious indirectness   Serious†††      None‡   ⊕⊕⊕ΟΟ\
                                                                                                                                                                       Low

  Ad libitum (n=4)            Randomised and non-randomised   No serious risk of bias   No serious inconsistency     No serious indirectness   Serious‡‡‡      None‡   ⊕⊕⊕Ο\
                                                                                                                                                                       Moderate
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GRADE=grading of recommendations assessment, development, and evaluation; Hb1Ac=glycated haemoglobin; MID=minimally important difference.

Serious inconsistency---evidence of significant interstudy heterogeneity; I^2^=82%, P\<0.001); serious imprecision---95% confidence interval (−0.35% to −0.08%, −27.3 to −24.4 mmol/mol) overlaps the MID for HbA1c (0.3%), including clinically unimportant benefit (≥−0.3%).

Serious inconsistency---evidence of significant interstudy heterogeneity (I^2^=83%, P\<0.001); serious imprecision---95% confidence interval (−0.41% to 0.50%, −28.0 to −18.0 mmol/mol) overlaps the MID for HbA1c (0.3%), including both clinically important benefit (≤−0.3%) and harm (≥0.3%).

Inconsistency cannot be excluded, because we were unable to test for heterogeneity owing to lack of studies (only one study included in the analysis); bias cannot be excluded, because we were unable to test for funnel plot asymmetry owing to lack of power (\<10 studies included in the analysis).

Serious indirectness---only one study of 240 overweight/obese female participants was available for analysis; serious imprecision---95% confidence interval (−0.04% to 0.14%, −23.9 to −22.0 mmol/mol) overlaps the MID for HbA1c (0.3%), including clinically unimportant benefit (≥−0.3%).

Serious indirectness---only one study of 10 participants with type 1 diabetes mellitus was available for analysis; serious imprecision---95% confidence interval (−0.38% to 0.42%, −27.7 to −18.9 mmol/mol) overlaps the MID for HbA1c (0.3%), including both clinically important benefit (≤−0.3%) and harm (≥0.3%).

Serious inconsistency---evidence of significant interstudy heterogeneity (I^2^=65%, P\<0.001); serious imprecision---95% confidence interval (−0.02 to 0.05 mmol/L) overlaps the MID for fasting blood glucose (0.5 mmol/L), including clinically unimportant benefit (≥−0.5 mmol/L).

Serious inconsistency---evidence of significant intersudy heterogeneity (I^2^=71%, P\<0.001); serious imprecision---95% confidence interval (−0.00 to 0.15 mmol/L) overlaps the MID for fasting blood glucose (0.5 mmol/L), including clinically unimportant benefit (≥−0.5 mmol/L).

No serious inconsistency---removal of the 2012 study by Tate and colleagues[@ref148] explained most of the heterogeneity (I^2^=32%, P=0.23), without changing the direction or significance of the effect on fasting blood glucose (mean difference 0.20 mmol/L (95% confidence interval 0.00 to 0.40), P=0.05), and removal of the 2015 study by Campos and colleagues (group 2)[@ref60] explained all the heterogeneity (I^2^=0%, P=0.78), changing the direction but not the lack of significance of the effect on fasting blood glucose (−0.02 mmol/L (−0.11 to 0.07), P=0.63); serious imprecision---95% confidence interval (−0.07 to 0.10 mmol/L) overlaps the MID for fasting blood glucose (0.5 mmol/L), including clinically unimportant benefit (≥−0.5 mmol/L).

Serious imprecision---95% confidence interval (−0.07 to 0.04 mmol/L) overlaps the MID for fasting blood glucose (0.5 mmol/L), including clinically unimportant benefit (≥−0.5 mmol/L).

Serious inconsistency---evidence of significant interstudy heterogeneity (I^2^=61%, P\<0.001); serious imprecision---95% confidence interval (−0.39 to 4.83 pmol/L) overlaps the MID for fasting blood insulin (10 pmol/L), including clinically unimportant benefit (≥−10 pmol/L).

Serious inconsistency---evidence of significant interstudy heterogeneity (I^2^=58%, P\<0.001); serious imprecision---95% confidence interval (−1.40 to 7.96 pmol/L) overlaps the MID for fasting blood insulin (10 pmol/L), including clinically unimportant benefit (≥−10 pmol/L).

Serious inconsistency---although the evidence of significant interstudy heterogeneity (I^2^=79%, P\<0.01) was explained by the removal of the 2015 study by Campos and colleagues (group 2)[@ref60] (I^2^=1%, P=0.31), the conclusion changed for the significance (from non-significant to significant) and magnitude (from smaller to larger) of the effect on fasting blood insulin (mean difference −39.54 pmol/L (95% confidence interval −75.02 to −4.06 pmol/L), P=0.03); serious imprecision---95% confidence interval (−26.83 to 22.83 pmol/L) overlaps the MID for fasting blood insulin (10 pmol/L), including both clinically important benefit (\<10 pmol/L) and harm (\>10 pmol/L). Only three studies involving 33 participants were available for analysis.

Serious imprecision---95% confidence interval (0.47 to 14.00 pmol/L) overlaps the MID for fasting blood insulin (10 pmol/L), including clinically unimportant harm (\>10 pmol/L).

Discussion
==========

Our systematic review and meta-analysis of 155 studies including 5086 participants with and without diabetes showed variable effects of food sources of fructose-containing sugars on three outcome measures of glycaemic control at median doses ranging from 12.2% to 23% of total energy intake over median follow-up durations of 4.5-12 weeks.

Four types of study designs were identified on the basis of energy control. In substitution studies, total food sources of fructose-containing sugars in energy matched comparisons with other macronutrients (mainly refined starches) showed a beneficial effect on HbA1c with no effects on fasting blood glucose or insulin, while individual food sources showed decreasing (fruit juice), null (fruit, SSBs, baked goods, added sweeteners), or increasing (sweetened milk, mixed sources) effects on fasting blood insulin. In addition studies, total food sources of fructose-containing sugars supplementing diets with excess energy compared to the same diet alone without the excess energy showed a harmful effect on fasting blood insulin without affecting HbA1c or fasting blood glucose, while individual food sources showed harmful effects on both fasting blood glucose (SSBs and fruit juice) and insulin (SSBs, mixed sources). In the ad libitum studies, total food sources of fructose-containing sugars freely replacing other macronutrients showed a harmful effect on fasting blood insulin (for which the effect was derived exclusively from mixed food sources inclusive of SSBs) without affecting HbA1c or fasting blood glucose. No effect of food sources of fructose-containing sugars was observed in subtraction studies.

Sources of heterogeneity
------------------------

Methodological and clinical sources of heterogeneity had an influence on our results. Sensitivity analyses showed evidence of instability in the significance of our pooled estimates. Removal of any one of six studies[@ref38] [@ref46] [@ref72] [@ref105] [@ref114] [@ref123] changed the estimates from non-significant to significant for fasting blood glucose in the addition studies, while the removal of a 2000 study by Raben and Astrup (C)[@ref124] changed the estimates from significant to non-significant for fasting blood insulin in the ad libitum studies. None of the studies explained any of the heterogeneity. Removal of the study by Campos and colleagues (group 2),[@ref60] however, did explain the heterogeneity and as well as change the significance of the effect. This sensitivity analysis revealed a consistent beneficial effect of reducing excess calories from fructose-containing sugars on fasting blood insulin in subtraction studies. The reason for the strong influence of this study is unclear. As the Campos study[@ref60] was small (n=15) and received most of the weight in the analysis (\>50%), its true within-study variances could have been seriously underestimated, leading to an important outlier effect on the pooled estimate for fasting blood insulin.[@ref153]

Subgroup analyses also showed evidence of effect modification under certain conditions. Greater improvements in fasting blood glucose were observed in participants with higher baseline fasting glucose in substitution and addition studies, suggesting a regression to the mean. These effects accorded with the observed subgroup modification by underlying disease status in addition studies, showing a greater beneficial effect on fasting blood glucose in patients with diabetes. A significant subgroup effect by level of feeding control and age were also observed in addition studies where fasting blood glucose was significantly reduced when dietary advice was the method of feeding control or the age of participants was 18 years or younger, but only one study was available for each of these analyses and neither analysis explained the substantial heterogeneity. The relevance of the subgroup analysis for feeding control was also brought into question when we found an opposite result for fasting blood insulin in substitution studies. The dose-response analyses showed a significant effect modification by dose, whereby HbA1c (continuous dose threshold analyses) and fasting blood glucose (categorical analyses) were lower at doses of up to 10% energy in substitution studies, suggesting that intake meeting current recommendations to consume no more than 10% of energy from free or added sugars[@ref22] [@ref33] might have advantages. No further advantages were seen at the other public health thresholds of 5% free sugars[@ref22] [@ref23] and 25% added sugars.[@ref34]

Results in the context of other studies
---------------------------------------

Our findings agree with two other systematic reviews and meta-analyses of controlled intervention studies, which showed a beneficial effect of the isocaloric substitution of fructose for other carbohydrates on glycated blood proteins in participants with diabetes (equivalent to about 0.53% reduction in HbA1c)[@ref13] and without diabetes (fructose intake \<90 g/day significantly improved HbA1c, dependent on dose, study duration, and severity of dysglycaemia).[@ref154] The modest decrease of −0.22% in HbA1c from our analysis did not exceed the clinically meaningful threshold of 0.3% proposed by the US Food and Drug administration for the development of new drugs for diabetes as observed in the previous meta-analysis.[@ref32] However, our findings suggest that food sources of fructose-containing sugars might have modest benefits for long term glycaemic control when they replace other macronutrients on a calorie-for-calorie basis. On the other hand, our results suggest that food sources of fructose-containing sugars providing excess energy to the diet could raise fasting blood insulin, according with the findings from our previous systematic reviews and meta-analyses that fructose providing excess energy increases insulin resistance.[@ref155]

Our data also agree with evidence from prospective cohort studies of the relation of fructose-containing sugars with diabetes risk. Although we failed to observe an adverse association of total fructose-containing sugars independent of food source with incident diabetes in an earlier systematic review and meta-analysis of the available prospective cohort studies,[@ref156] differential associations have been shown for different food sources of sugars. Systematic reviews and meta-analyses of prospective cohort studies have shown an adverse association with SSBs[@ref16] [@ref17] but a protective association with fruit,[@ref18] [@ref19] associations which are consistent with our findings of a harmful effect of SSBs on fasting blood glucose and insulin in addition studies and beneficial effect of fruit on HbA1c in substitution studies.

Potential mechanisms
--------------------

Several proposed mechanisms could explain the observed beneficial effect of food sources of fructose-containing sugars on HbA1c when substituted for other calories in the diet. Fructose has a relatively low glycaemic index (GI) of 16, compared with reference carbohydrates such as starch with a GI of 100.[@ref157] Most of the comparators used in substitution studies were in the form of starch, so replacement of these high GI carbohydrates with fructose could have reduced the overall GI of the diet, leading to long term glycaemic improvement[@ref158] through alleviation of β cell stress.[@ref159] [@ref160] Evidence also suggests that high GI diets are associated with reliable clinical markers of insulin resistance, such as higher triglycerides and lower high density lipoprotein cholesterol.[@ref161] [@ref162]

The low GI of fruit could explain why it was the main food source driving a significant improvement in HbA1c in substitution studies, especially when compared with intermediate GI food sources such as SSBs or sweets, which provide calories from sugars in the absence of any nutritional value. The higher fibre content of fruit could contribute to lower postprandial glycaemic excursions. Particularly, viscous gels formed by the pectin in fruit could delay gastric emptying and slow down the release of sugars.[@ref163] A secondary analysis of a randomised controlled trial of the effect of a six month, low GI intervention showed that low GI fruit intake was the strongest predictor of HbA1c reduction in people with type 2 diabetes.[@ref164] Whether low GI food sources of fructose-containing sugars would show similar effects to those of other low GI carbohydrate foods (including legumes or some whole grains) remains unknown, owing to a lack of studies using high quality carbohydrate comparators.

While a low GI mechanism could have contributed to the observed decrease in HbA1c in the substitution studies), especially as it relates to fruit, it did not extend to improvements in fasting blood glucose and insulin. Although the summary effect estimates for both outcomes tended to be in the direction of benefit (with the possibility of additional studies providing sufficient power to confirm any beneficial effects), a mechanism that targets postprandial excursions in glucose and insulin would not necessarily be expected to lead to meaningful improvements in these fasting measurements, which are determined more by changes in insulin sensitivity.[@ref158]

An alternative mechanism accounting for the observed beneficial effects of food sources of fructose-containing sugars on HbA1c in substitution studies relates to a so-called "catalytic" effect of fructose, whereby fructose metabolites have regulatory actions on glucokinase and hepatic glucose uptake. Evidence indicates that fructose, especially at small doses of up to 10 g/meal (a level obtainable from fruit), could improve glycaemia by the ability of fructose-1-P to up regulate glucokinase activity through the glucokinase regulatory protein, resulting in decreased hepatic glucose production[@ref165] and increased glycogen synthesis.[@ref166] The relevance of this mechanism is unclear. It has not been reliably shown[@ref167] [@ref168] under different experimental conditions, and would be expected to have disproportionally greater effect on fasting blood glucose and insulin than HbA1c, the opposite of what we found in the present study. How dietary fructose interacts with glucose at the level of hepatic glucose homeostasis remains largely underexplored.

The increase in insulin in the absence of a harmful effect on HBA1c or fasting blood glucose with sweetened low fat milk in the substitution studies could relate to an isolated insulinotropic effect of dairy proteins. The ability of protein, especially dairy proteins, co-ingested with carbohydrate to stimulate glucose stimulated insulin secretion has been well described.[@ref169] [@ref170] [@ref171] This isolated finding does not necessarily imply harm, because fasting glucose was not increased and sweetened and unsweetened low fat dairy, especially in the form of yogurt, is associated with decreased risk of weight gain and diabetes incidence.[@ref172]

By contrast, the observed harmful effects of food sources of fructose-containing sugars on glycaemic control in addition studies seem to be largely driven by the energy contribution of the sugars. Fructose-containing sugars supplementing diets with excess calories could promote ectopic weight gain, contributing to downstream insulin resistance and impaired glycaemic control. Related effects have been reported in systematic reviews and meta-analyses of controlled intervention studies of fructose overfeeding for body weight,[@ref173] blood pressure,[@ref174] uric acid levels,[@ref175] markers of non-alcoholic fatty liver disease,[@ref176] and postprandial triglycerides.[@ref177] Although fructose has been proposed to increase de novo lipogenesis more than other carbohydrates (owing to fructose's ability to enter glycolysis as an unregulated substrate), leading to weight gain and its downstream cardiometabolic disturbances, this mechanism has been shown to be a minor pathway for fructose disposal.[@ref178] The mechanism is also not unique to fructose-containing sugars, and weight gain with metabolic disturbances would be expected for the overconsumption of food sources of other dietary macronutrients.[@ref179]

The lack of a protective effect of interventions to reduce excess energy from food sources of fructose-containing sugars in subtraction studies is unclear. It could represent compensation, in which the decrease in energy from food sources of these sugars are compensated by replacement with energy from other food sources or spontaneous changes in physical activity that decrease energy expenditure, preventing weight loss and its downstream metabolic benefits. Compensation might have been more apparent in these studies because they had the longest median follow-up (12 weeks), and might explain why longer term subtraction studies (with median follow-up of roughly one year) designed to displace excess energy from SSBs have only shown a weight loss benefit in specific subgroups of overweight or obese individuals.[@ref180] The instability in the significance of the pooled effect estimates might have also had a role. Removal of the Campos study (group 2)[@ref60] explained the heterogeneity showing significant beneficial effects on fasting insulin, suggesting that this study might have masked a true benefit of interventions to reduce fructose-containing sugars.

Implications
------------

As dietary guidelines shift from a focus on individual nutrients towards a focus on foods and dietary patterns, our findings might have implications for guiding recommendations on important food sources of fructose-containing sugars in the prevention and management of diabetes. As various food sources of these sugars tended to show improvements in HbA1c, consumption of foods such as fruit, yogurt, and whole grain cereals to replace foods high in refined starches within the recommendation to consume no more than 10% of energy from free sugars[@ref22] [@ref32] might be an effective strategy to improve glycaemic control, especially in people with diabetes. As SSBs tended to impair fasting blood glucose and insulin when adding excess energy to the diet, public health strategies to reduce consumption of SSBs could be useful, especially as they provide empty calories in absence of any nutritional value. While these findings highlight the role of food sources of fructose-containing sugars on glycaemic control, other important cardiometabolic parameters should also be considered in future syntheses.

Strengths and limitations
-------------------------

Our systematic review and meta-analysis has several strengths. Firstly, we did a comprehensive and reproducible search and selection process of the literature examining the effect of food sources of fructose-containing sugars on glycaemic control. Secondly, collation and synthesis of all the available evidence from a large body (155 studies, n=5086) of controlled intervention studies was performed, providing maximum protection against bias (noting that results did not differ between randomised and non-randomised studies). Thirdly, we included an assessment of overall quality of evidence using the GRADE assessment approach.

Several of our analyses presented limitations. Firstly, despite the inclusion of many studies, a limited number of studies used particular food sources. For example, no comparison included sweetened breakfast cereals or yogurt, and only one study comparison was available for sweetened chocolate and two study comparisons for sweetened low fat milk for any of the analyses. Many analyses also had only one or two study comparisons available for inclusion: baked goods, sweets, and desserts for HbA1c in substitution and addition studies (one study); fruit juice for fasting blood glucose and insulin in substitution studies (one); mixed sources for fasting blood glucose and insulin in addition studies (one); SSBs for HbA1c in substitution studies (two); and fruit juice for fasting blood glucose in addition studies (two). As a result, we elected only to do GRADE assessments for total food sources. Secondly, substantial unexplained heterogeneity was present in all analyses for the substitution studies, as well as the addition studies for HbA1c, fasting blood glucose, and fasting blood insulin. Although we also saw substantial heterogeneity in the subtraction studies for HbA1c, fasting blood glucose, and insulin, and ad libitum studies for HbA1c, the removal of individual studies during sensitivity analyses explained this heterogeneity, and so we did not downgrade for inconsistency.

Thirdly, serious indirectness was present in some analyses, because only one trial of 240 overweight and obese women was available in the HbA1c subtraction analysis, and similarly, one trial of 10 patients with diabetes was available in the HbA1c ad libitum analysis. Although the small sample sizes of included studies (median ranging from 15 participants in subtraction studies to 39 participants in ad libitum studies) are another potential source of indirectness, we did not downgrade the evidence for indirectness owing to the large number of included studies, representing a diverse range of study conditions and metabolic phenotypes across many participants. We also did not downgrade for indirectness because of the relatively short duration of follow-up (median 4.5-12 weeks), and we believed that it was sufficient to assess the question of harm (a decision shared with an earlier WHO commissioned review of the evidence for sugars and body weight).[@ref181] Finally, we saw evidence of serious imprecision in all of the analyses. As the 95% confidence intervals crossed the minimally important differences for HbA1c, fasting blood glucose, and fasting blood insulin, these analyses were downgraded for serious imprecision. Weighing the strengths and limitations, we graded the quality in the evidence using GRADE as low for HbA1c, low to moderate for fasting blood glucose, and low to moderate for fasting blood insulin across the four study designs based on energy control.

Conclusion
----------

The effects of food sources of fructose-containing sugars on glycaemic control appear to be both energy and food source dependent. Food sources of fructose-containing sugars, especially fruit, substituted for equal amounts of calories from other macronutrient sources (mainly refined starches) led to improvements in HbA1c without adversely affecting fasting blood glucose or insulin. However, when several food sources of fructose-containing sugars added excess energy to the diet, especially SSBs, significant increases in fasting blood glucose and insulin were observed. The same result was also seen for mixed food sources (inclusive of SSBs) of fructose-containing sugars freely replacing other macronutrients on fasting blood insulin without a harmful effect on HbA1c or fasting blood glucose. The anticipated benefit of interventions to reduce the excess energy from sugars, however, was not seen reliably, suggesting that compensatory behaviours might be an important consideration. The lack of any harm and even advantages were most pronounced in those individuals with higher HbA1c and fasting blood glucose at baseline or who had diabetes.

Although our findings suggest that common food sources of fructose-containing sugars do not have harmful effects on glycaemic control in energy matched replacement of other less sugary foods, our GRADE assessment suggests that more research is likely to have an important influence on many of our estimates. More large, high quality studies using a greater variety of food sources of fructose-containing sugars are required to assess the durability of these effects and understand whether certain food sources with an apparent signal for benefit, such as fruit, might even have advantages for glycaemic control under free living conditions over the longer term (six months or longer). Meanwhile, policy and guidelines makers should consider the influence of energy control and food source in the development recommendations to reduce sugars for the prevention and management of diabetes.

### What is already known on this topic

1.  Current dietary guidelines recommend a reduction to less than 5-10% energy in free sugars, especially fructose-containing sugars from sugars-sweetened beverages (SSBs)

2.  In the published literature, fructose-containing sugars from SSBs have shown an adverse association with diabetes incidence, and free fructose adding excess energy to diets has shown a harmful effect on glycaemic control

3.  As dietary guidelines shift from a focus on single nutrients to a focus on dietary patterns, it is unclear whether the evidence for SSBs and excess energy from fructose holds for other important food sources of fructose-containing sugars at different levels of energy control

### What this study adds

1.  This systematic review and meta-analysis of 155 controlled intervention studies suggests that most food sources of fructose-containing sugars do not have a harmful effect on glycaemic control in energy matched substitutions for other macronutrients

2.  However, several food sources do have harmful effects when adding excess energy to the diet, especially SSBs

3.  Until more information is available, public health professionals should be aware that harmful effects of fructose-containing sugars on glycaemic control seem to be mediated by energy and food source
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